Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Working Capital Changes (2019 - 2025)

Historic Other Working Capital Changes for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$2.8 million.

  • Kymera Therapeutics' Other Working Capital Changes fell 1402.64% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 40005.81%. This contributed to the annual value of -$41.1 million for FY2024, which is 32104.73% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Other Working Capital Changes stood at -$2.8 million, which was down 1402.64% from $29.2 million recorded in Q2 2025.
  • Kymera Therapeutics' Other Working Capital Changes' 5-year high stood at $38.1 million during Q4 2023, with a 5-year trough of -$23.9 million in Q2 2024.
  • In the last 5 years, Kymera Therapeutics' Other Working Capital Changes had a median value of -$8.3 million in 2024 and averaged -$5.6 million.
  • In the last 5 years, Kymera Therapeutics' Other Working Capital Changes plummeted by 43628.35% in 2021 and then soared by 37987.8% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Other Working Capital Changes (Quarter) stood at -$15.1 million in 2021, then increased by 10.15% to -$13.6 million in 2022, then skyrocketed by 379.88% to $38.1 million in 2023, then plummeted by 116.94% to -$6.4 million in 2024, then surged by 57.13% to -$2.8 million in 2025.
  • Its last three reported values are -$2.8 million in Q3 2025, $29.2 million for Q2 2025, and -$2.8 million during Q1 2025.